Semaglutide Weight Loss Gainesville FL

How Semaglutide Works, GLP-1 Receptor Agonist Mechanism

Semaglutide is a GLP-1 receptor agonist, a synthetic peptide that mimics glucagon-like peptide 1, a hormone that regulates blood sugar and appetite. When you inject semaglutide, it activates GLP-1 receptors in your brain, signaling fullness and reducing hunger. Simultaneously, it slows gastric emptying, extending the feeling of satiety after meals.

The result: dramatically reduced appetite without willpower or restrictive dieting. Patients on semaglutide naturally eat 300 to 500 fewer calories per day because they feel fuller longer. Combined with light exercise and balanced nutrition, this creates a sustained calorie deficit, the foundation of healthy weight loss.

At Bespoke Aesthetics, Dr. Indianos prescribes compounded semaglutide, a GLP-1 receptor agonist, and monitors your response via baseline labs, injection training, dose escalation protocols, and ongoing telemedicine plus in-person follow-ups. Your dosing is personalized to your metabolism, not the standard dose most apps use.

Semaglutide Results, What to Expect, Week by Week

Weeks 1 to 2: a starting dose determined by your physician; mild appetite suppression; possible mild nausea (subsides in 1 to 2 weeks with dietary adjustment).

Weeks 2 to 4: weight loss becomes noticeable (2 to 4 lbs); nausea typically resolves; increased fullness sensation with smaller meals.

Weeks 4 to 8: dose adjustments determined by your physician; accelerated weight loss; energy increases as metabolism stabilizes.

Weeks 8 to 12: a maintenance dose determined by your physician; sustained, gradual weight loss (individual results vary); appetite remains suppressed; comfortable eating smaller, nutrient-dense portions.

Months 3 to 6: continued, gradual weight loss with adherence and dietary support; individual results vary.

Ongoing maintenance: once goal weight is reached, transition to a maintenance dose determined by your physician with quarterly check-ins. Maintenance requires continued medication use; discontinuation typically results in appetite return.

This schedule reflects what Dr. Indianos typically prescribes based on patient response, and is provided for general education, not as instructions to follow on your own. Your starting dose, titration schedule, and any adjustments are determined individually after an in-person medical evaluation with Dr. Indianos, and may differ from what is shown here.

These are typical results with medical supervision; individual variation is normal. Dr. Indianos discusses realistic expectations for your specific baseline and health history.

Semaglutide Side Effects, Management Strategies

Most common side effects are gastrointestinal: nausea (40 to 50% of patients), vomiting, constipation, diarrhea. These are typically mild-to-moderate and subside within 2 to 3 weeks as your body adjusts.

Nausea management: eat smaller, more frequent meals; avoid fatty or spicy foods; increase hydration; consider ginger supplements or anti-nausea medication (prescription available).

Constipation: increase fiber intake gradually, drink 80+ oz water daily, consider magnesium supplement, light daily exercise.

Diarrhea: reduce fiber temporarily, eat bland foods (rice, chicken, toast), avoid artificial sweeteners.

Serious side effects (rare with physician supervision): pancreatitis (abdominal pain), thyroid concerns (family history of thyroid cancer is a contraindication), gallbladder issues. Dr. Indianos screens for contraindications during your baseline consultation.

Semaglutide vs. Tirzepatide, Which Is Right for You?

The brand-name versions (Wegovy for semaglutide, Zepbound for tirzepatide) are FDA-approved for chronic weight management. Compounded semaglutide and tirzepatide are not FDA-approved. The key difference is mechanism of action.

Semaglutide (GLP-1 agonist): in clinical trials of brand-name Wegovy, patients lost an average of roughly 15% of body weight over about 68 weeks (STEP); single hormone mechanism (appetite suppression); longer market history; good for straightforward weight loss and mild metabolic dysfunction.

Tirzepatide (GIP/GLP-1 agonist): in clinical trials of brand-name Zepbound, patients lost roughly 15 to 21% of body weight over about 72 weeks (SURMOUNT); dual hormone mechanism (appetite plus glucose regulation); newer; particularly effective for insulin resistance, PCOS, and metabolic dysfunction. Compounded formulations have not been studied in these trials.

Dr. Indianos reviews your baseline labs (fasting insulin, glucose, A1C, lipid panel) and health history to recommend the medication best suited to your individual metabolism. Many patients start with semaglutide and escalate to tirzepatide if results plateau.